# Study to Assess Safety and Efficacy of Treating Symptomatic, Ischemic, Chronic Congestive Heart Failure Patients with an LVEF of ≤40% with Fresh, Uncultured, Autologous, Adipose-derived Regenerative Cells Isolated from Lipoaspirate.

> **NCT06705023** · PHASE2 · RECRUITING · sponsor: **Ralf Rothoerl** · enrollment: 36 (estimated)

## Conditions studied

- Myocardial Injury
- LV Dysfunction
- Coronary Artery Disease
- Heart Failure

## Interventions

- **BIOLOGICAL:** Uncultured, autologous, adipose-derived regenerative cells (UA-ADRCs)
- **OTHER:** Continuation of patient's best guideline based medical treatment

## Key facts

- **NCT ID:** NCT06705023
- **Lead sponsor:** Ralf Rothoerl
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-18
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-12-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06705023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06705023, "Study to Assess Safety and Efficacy of Treating Symptomatic, Ischemic, Chronic Congestive Heart Failure Patients with an LVEF of ≤40% with Fresh, Uncultured, Autologous, Adipose-derived Regenerative Cells Isolated from Lipoaspirate.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06705023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*